Trump to Fire FDA Chief Makary

Good morning, healthcare professional.

Leadership upheaval at the FDA, a major AI diagnostics acquisition, and billions in manufacturing investment dominate today's healthcare landscape. President Trump reportedly plans to remove FDA Commissioner Marty Makary, while Roche bets three-quarters of a billion dollars on artificial intelligence in pathology.

These developments signal shifting regulatory priorities and accelerating technology adoption across the pharmaceutical sector. From Supreme Court decisions on medication access to unprecedented capital commitments for drug production, today's stories reveal an industry navigating political uncertainty while doubling down on innovation and capacity.

In today's healthcare digest:

• FDA Commissioner Makary faces reported removal amid controversial tenure
• Roche acquires PathAI for $750 million upfront in AI diagnostics push
• Eli Lilly commits $4.5 billion to Indiana manufacturing expansion
• Supreme Court temporarily preserves mifepristone access during litigation

FDA Leadership Shakeup: Trump Plans Makary Removal

President Trump reportedly plans to remove FDA Commissioner Marty Makary from his position, marking a dramatic turn after a controversial tenure at the agency. Both Fierce Pharma and STAT News confirmed the reports.

• The move comes amid ongoing debates about FDA policy direction and regulatory decisions under Makary's leadership.
• Commissioner dismissals are rare events that typically signal major shifts in agency priorities and enforcement approaches.
• Pending drug approvals, regulatory policy initiatives, and agency morale could face significant disruption during transition.

Roche Bets Big on AI Pathology with PathAI Acquisition

Roche announced plans to acquire PathAI, an artificial intelligence pathology company, for $750 million upfront. This major acquisition represents significant investment in AI-powered diagnostics and digital pathology technology.

• PathAI's AI algorithms are designed to improve accuracy and efficiency in pathology analysis across multiple disease areas.
• The deal underscores pharmaceutical companies' commitment to integrating advanced technology into diagnostic workflows and drug development.
• Roche gains immediate access to AI capabilities that could accelerate clinical trial enrollment and companion diagnostics development.

Eli Lilly Invests $4.5 Billion in Indiana Manufacturing

Eli Lilly will invest an additional $4.5 billion in manufacturing facilities across Indiana, significantly expanding production capacity likely for blockbuster diabetes and obesity drugs Mounjaro and Zepbound. This substantial capital investment demonstrates the company's commitment to meeting surging demand for GLP-1 medications.

• The expansion represents one of the largest single manufacturing investments in the pharmaceutical industry this year.
• Lilly faces persistent supply constraints for its GLP-1 drugs as demand continues outpacing production capacity.
• The Indiana facilities will likely create hundreds of jobs while strengthening domestic pharmaceutical manufacturing capabilities.

Supreme Court Extends Mifepristone Access Temporarily

The U.S. Supreme Court issued a temporary extension of women's access to mifepristone, a widely used abortion medication, while legal challenges continue. This decision maintains the current regulatory framework for the drug's distribution and use during ongoing litigation.

• The ruling preserves existing FDA-approved prescribing practices, including telemedicine access and mail delivery options.
• The case raises fundamental questions about FDA regulatory authority over approved medications beyond reproductive health.
• Healthcare providers and pharmaceutical companies are closely monitoring implications for drug approval processes and agency autonomy.

The Shortlist

• Bristol Myers Squibb partnered with China's Hengrui Pharma on a dozen drugs, expanding its presence in the Chinese pharmaceutical market.

• Daiichi Sankyo targets global top 5 oncology rank by 2035 with a $1.3 billion efficiency drive in its new five-year strategic plan.

• GSK cut a deal with Sino to broaden reach of its hepatitis B drug bepirovirsen in China.

• Astellas resumed gene therapy trials for myotubular myopathy five years after a devastating setback, offering renewed hope to the rare disease community.

• Biotech layoffs are easing according to new data, though questions remain whether the worst of the industry downturn is over.